Jordyn Sava is an editor for Targeted Oncology.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL
November 22nd 2022In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.
Managing Patients in the Changing Treatment Landscape of ALL
November 21st 2022In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed managing patients with different subtypes of ALL and the session he was a part of during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Study Looks for Ways to Reduce Incidence of Tobacco-Associated Pancreatic Cancer
November 17th 2022In an interview with Targeted Oncology, Nagaraj Nagathihalli, PhD, further explained the basis behind his study examining tobacco-associated pancreatic cancer and his plans to improve overall survival in this patient population.
PSMA-PET SUVmean Linked With Favorable Response to 177Lu-PSMA-617 in mCRPC
November 17th 2022Findings from the phase 2 TheraP trial showed 177Lu-PSMA-617 to result in a higher prostate-specific antigen response rate vs with cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Phase 3 FRUTIGA Study of Fruquintinib Elicits Positive Results in Gastric/GEJ Cancers
November 16th 2022Fruquintinib plus paclitaxel demonstrated improvements in progression-free survival, objective response rate, disease control rate, and more, in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Best Uses of Transplantation for Patients With Peripheral T-Cell Lymphoma
November 15th 2022Randomized studies examining patients with peripheral T-cell lymphoma regarding the role of transplant are lacking and more research is needed to personalize therapy for patients based on subtype, biomarkers, mutational profiling, and radiographic parameters.
FDA Approves Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Cancer
November 14th 2022Mirvetuximab soravtansine has been granted FDA accelerated approval for use in patients with folate receptor alpha-high platinum-resistant ovarian cancer who have received prior treatment with 1 to 3 prior systemic therapies.
FDA Approves Brentuximab Vedotin for Pediatric Patients With High-Risk Hodgkin Lymphoma
November 10th 2022Based on results from the phase 3 AHOD1331 trial, the FDA has approved brentuximab vedotin in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients with high-risk classical Hodgkin lymphoma.
Novel IO Vaccine Induces Immune Response HPV16-Positive Tumors
November 9th 2022A first-in-human study investigating the safety and immunogenicity of amplivant adjuvant and human papillomavirus type 16 synthetic long peptides demonstrated highly favorable safety and tolerability when used as an intradermal therapeutic vaccine.
Mirvetuximab Shows Potential as New Standard of Care for FRα-Expressing Ovarian Cancer
November 8th 2022In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discussed the pooled analysis of 3 studies which examined single agent mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
GOBLET Trial’s Pancreatic Cohort Displays High Efficacy With Pelareorep/Atezolizumab
November 8th 2022Treatment with pelareorep plus atezolizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma led to an overall response rate nearly triple than the average which were previously reported in historical control trials.
Frontline Pembrolizumab Monotherapy Continues to Elicit Clinical Benefit vs Chemo in NSCLC
November 7th 2022Five-year data from the phase 3 KEYNOTE-042 shows that patients with non–small cell lung cancer without EGFR/ALK alterations continue to elicit durable benefit with pembrolizumab monotherapy vs chemotherapy.
Milademetan Shows Promise for Patients With Advanced MDM2-Mutated Solid Tumors
November 7th 2022The interim analysis of the phase 2 MANTRA-2 trial of milademetan, an MDM2 inhibitor, has demonstrated promising safety and activity in patients with advanced solid tumors. The trial will continue enrolling patients.
Lintuzumab-Ac225 and Intensive Chemotherapy Elicits High Response Rates in AML
November 3rd 2022The phase 1 study of lintuzumab-Ac225 combined with the CLAG-M regimen in acute myeloid leukemia demonstrated positive response rates, including an overall survival rate of 53% at 1-year and 32% at 2-years.